Immune checkpoint inhibitors that target programmed cell death protein 1 (PD-1) or PD1 ligand 1 (PD-L1) have demonstrated activity in relapsed mesothelioma and are undergoing further evaluation. The gene discussed is PDCD1; the disease is mesothelioma.